Home LiteratureArticle Details
PMID: 8531887 Published · ppublish English Journal Article Review

Streptococcus pneumoniae: virulence factors, pathogenesis, and vaccines.

Microbiological reviews ·Vol. 59 ·No. 4 ·1995-12-00 ·Pages 591-603

AlonsoDeVelasco E, Verheul AF, Verhoef J, Snippe H

Abstract

Although pneumococcal conjugate vaccines are close to being licensed, a more profound knowledge of the virulence factors responsible for the morbidity and mortality caused by Streptococcus pneumoniae is necessary. This review deals with the major structures of pneumococci involved in the pathogenesis of pneumococcal disease and their interference with the defense mechanisms of the host. It is well known that protection against S. pneumoniae is the result of phagocytosis of invading pathogens. For this process, complement and anticapsular polysaccharide antibodies are required. Besides, relatively recent experimental data suggest that protection is also mediated by the removal of disintegrating pneumococci and their degradation products (cell wall, pneumolysin). These structures seem to be major contributors to illness and death caused by pneumococci. An effective conjugate vaccine should therefore preferably include the capsular polysaccharide and at least one of these inflammatory factors.

MeSH Terms
Adult Antigens, Bacterial/immunology Bacterial Proteins/immunology,physiology Bacterial Vaccines/immunology Child Child, Preschool Humans Infant Pneumococcal Infections/epidemiology,immunology,microbiology Streptococcus pneumoniae/chemistry,pathogenicity,ultrastructure Virulence
Chemicals
Antigens, Bacterial Bacterial Proteins Bacterial Vaccines
Authors & Affiliations
4 authors, click to expand affiliations / ORCID
AlonsoDeVelasco E
Eijkman-Winkler Institute of Medical and Clinical Microbiology, University Hospital, Utrecht, The Netherlands.
Verheul A F
Verhoef J
Snippe H
References (158)
158 references, click to expand
  1. Does naturally acquired IgG antibody to cell wall polysaccharide protect human subjects against pneumococcal infection?
    J Infect Dis. 1990 Apr;161(4):736-40 PMID: 2319167
  2. Serotypes of Streptococcus pneumoniae causing disease.
    J Infect Dis. 1979 Dec;140(6):979-83 PMID: 44310
  3. Opposite effects of actively and passively acquired immunity to the carrier on responses of human infants to a Haemophilus influenzae type b conjugate vaccine.
    Infect Immun. 1994 Jan;62(1):9-14 PMID: 8262653
  4. Immunogenicity of Streptococcus pneumoniae type 14 capsular polysaccharide: influence of carriers and adjuvants on isotype distribution.
    Infect Immun. 1991 Aug;59(8):2750-7 PMID: 1855991
  5. Degradation of C3 by Streptococcus pneumoniae.
    J Infect Dis. 1994 Sep;170(3):600-8 PMID: 8077717
  6. Western blot analysis of immunoglobulin G antibodies to pneumococcal protein antigens in healthy adults.
    Eur J Clin Microbiol Infect Dis. 1991 Feb;10(2):73-6 PMID: 1864278
  7. Activation of the alternative pathway by pneumococcal cell walls.
    J Immunol. 1977 Feb;118(2):451-4 PMID: 14211
  8. Susceptibility of Streptococcus pneumoniae to penicillin: a prospective microbiological and clinical study.
    Clin Infect Dis. 1992 Feb;14(2):427-35 PMID: 1554828
  9. Pneumococcal polysaccharides complexed with C3d bind to human B lymphocytes via complement receptor type 2.
    Infect Immun. 1991 May;59(5):1839-45 PMID: 1826897
  10. Chronic granulomatous disease.
    Pediatr Clin North Am. 1977 May;24(2):365-76 PMID: 323805
  11. Pneumococcal vaccine: a tool for the evaluation of the B-cell function of the immune system.
    Proc Soc Exp Biol Med. 1983 Dec;174(3):309-15 PMID: 6364146
  12. The induction of meningeal inflammation by components of the pneumococcal cell wall.
    J Infect Dis. 1985 May;151(5):859-68 PMID: 3989321
  13. Peptide permeases from Streptococcus pneumoniae affect adherence to eucaryotic cells.
    Infect Immun. 1995 Jul;63(7):2493-8 PMID: 7790061
  14. Opsonic requirements for phagocytosis of Streptococcus pneumoniae types VI, XVIII, XXIII, and XXV.
    Infect Immun. 1977 Nov;18(2):291-7 PMID: 21849
  15. Regulation of magnitude of antibody response to bacterial polysaccharide antigens by thymus-derived lymphocytes.
    Infect Immun. 1990 Nov;58(11):3465-8 PMID: 2228218
  16. CHEMO-IMMUNOLOGICAL STUDIES ON CONJUGATED CARBOHYDRATE-PROTEINS : II. IMMUNOLOGICAL SPECIFICITY OF SYNTHETIC SUGAR-PROTEIN ANTIGENS.
    J Exp Med. 1929 Sep 30;50(4):533-50 PMID: 19869645
  17. Effects of pH and polysaccharides on peptide binding to class II major histocompatibility complex molecules.
    Proc Natl Acad Sci U S A. 1991 Apr 1;88(7):2740-4 PMID: 2011583
  18. Pneumococcal polysaccharide vaccines: indications, efficacy and recommendations.
    Eur J Clin Microbiol Infect Dis. 1991 Nov;10(11):897-910 PMID: 1794358
  19. The epitope associated with the binding of the capsular polysaccharide of the group B meningococcus and of Escherichia coli K1 to a human monoclonal macroglobulin, IgMNOV.
    J Exp Med. 1988 Aug 1;168(2):699-711 PMID: 2457648
  20. Immunization of mice with pneumolysin toxoid confers a significant degree of protection against at least nine serotypes of Streptococcus pneumoniae.
    Infect Immun. 1994 Dec;62(12):5683-8 PMID: 7960154
  21. Synthetic peptides as vaccines.
    Curr Opin Immunol. 1992 Aug;4(4):449-53 PMID: 1382452
  22. Receptor specificity of adherence of Streptococcus pneumoniae to human type-II pneumocytes and vascular endothelial cells in vitro.
    Microb Pathog. 1994 Dec;17(6):361-74 PMID: 7752878
  23. Pneumolysin stimulates production of tumor necrosis factor alpha and interleukin-1 beta by human mononuclear phagocytes.
    Infect Immun. 1994 Apr;62(4):1501-3 PMID: 8132361
  24. A comparative study of the immunogenicity of pneumococcal type 4 polysaccharide and oligosaccharide tetanus toxoid conjugates in adult mice.
    J Immunol. 1991 Jun 15;146(12):4308-14 PMID: 2040803
  25. Immaturity of the human splenic marginal zone in infancy. Possible contribution to the deficient infant immune response.
    J Immunol. 1989 Nov 15;143(10):3200-6 PMID: 2478621
  26. Immunogenic properties in mice of hexasaccharide from the capsular polysaccharide of Streptococcus pneumoniae type 3.
    Infect Immun. 1983 Jun;40(3):856-61 PMID: 6852923
  27. Analysis of antigenicity and immunogenicity of five different chemically defined constructs of a peptide.
    Mol Immunol. 1992 Jun;29(6):793-800 PMID: 1603096
  28. The role of antibody and complement in the reticuloendothelial clearance of pneumococci from the bloodstream.
    Rev Infect Dis. 1983 Sep-Oct;5 Suppl 4:S797-805 PMID: 6356294
  29. STUDIES ON THE CHEMICAL NATURE OF THE SUBSTANCE INDUCING TRANSFORMATION OF PNEUMOCOCCAL TYPES : INDUCTION OF TRANSFORMATION BY A DESOXYRIBONUCLEIC ACID FRACTION ISOLATED FROM PNEUMOCOCCUS TYPE III.
    J Exp Med. 1944 Feb 1;79(2):137-58 PMID: 19871359
  30. Epidemiologic studies of Streptococcus pneumoniae in infants: acquisition, carriage, and infection during the first 24 months of life.
    J Infect Dis. 1980 Dec;142(6):923-33 PMID: 7462701
  31. Pneumococcal proteins and the pathogenesis of disease caused by Streptococcus pneumoniae.
    J Gen Microbiol. 1992 Feb;138(2):249-59 PMID: 1564436
  32. Repertoire diversity of antibody response to bacterial antigens in aged mice. III. Phosphorylcholine antibody from young and aged mice differ in structure and protective activity against infection with Streptococcus pneumoniae.
    J Immunol. 1993 Jan 15;150(2):543-9 PMID: 8419487
  33. Lectinophagocytosis: a molecular mechanism of recognition between cell surface sugars and lectins in the phagocytosis of bacteria.
    Infect Immun. 1988 Mar;56(3):539-47 PMID: 2893771
  34. Contribution of autolysin to virulence of Streptococcus pneumoniae.
    Infect Immun. 1989 Aug;57(8):2324-30 PMID: 2568343
  35. Immunization of humans with polysaccharide vaccines induces systemic, predominantly polymeric IgA2-subclass antibody responses.
    J Immunol. 1990 May 15;144(10):3770-8 PMID: 2110213
  36. Pneumococcal surface protein A (PspA) is serologically highly variable and is expressed by all clinically important capsular serotypes of Streptococcus pneumoniae.
    Infect Immun. 1990 Oct;58(10):3293-9 PMID: 1698178
  37. Opsonization and antibodies to capsular and cell wall polysaccharides of Streptococcus pneumoniae.
    J Infect Dis. 1994 Sep;170(3):592-9 PMID: 8077716
  38. Mouse antibody to phosphocholine can protect mice from infection with mouse-virulent human isolates of Streptococcus pneumoniae.
    Infect Immun. 1992 May;60(5):1957-62 PMID: 1563788
  39. Characterization of the antibody response to type 3 pneumococcal polysaccharide at the cellular level. 3. Studies on the average avidity of the antibody produced by specific plaque-forming cells.
    J Immunol. 1971 Sep;107(3):719-24 PMID: 4398381
  40. Analysis of thymus-independent type 2 antigen uptake by marginal zone macrophages in thin slices of viable lymphoid tissue in vitro.
    Eur J Immunol. 1990 Jul;20(7):1451-5 PMID: 1696891
  41. Antigen-specific interaction between T and B cells.
    Nature. 1985 Apr 11-17;314(6011):537-9 PMID: 3157869
  42. Influence of epitope polarity and adjuvants on the immunogenicity and efficacy of a synthetic peptide vaccine against Semliki Forest virus.
    J Virol. 1993 Oct;67(10):5843-8 PMID: 7690411
  43. Role of the bacterial cell wall in middle ear inflammation caused by Streptococcus pneumoniae.
    Infect Immun. 1992 Jul;60(7):2850-4 PMID: 1612750
  44. Anti-polysaccharide immunoglobulin isotype levels and opsonic activity of antisera: relationships with protection against Streptococcus pneumoniae infection in mice.
    J Infect Dis. 1995 Aug;172(2):562-5 PMID: 7622906
  45. Reduced virulence of a defined pneumolysin-negative mutant of Streptococcus pneumoniae.
    Infect Immun. 1989 Jul;57(7):2037-42 PMID: 2731982
  46. Epitope specificity of rabbit immunoglobulin G (IgG) elicited by pneumococcal type 23F synthetic oligosaccharide- and native polysaccharide-protein conjugate vaccines: comparison with human anti-polysaccharide 23F IgG.
    Infect Immun. 1994 Mar;62(3):799-808 PMID: 7509318
  47. IgG2 subclass restriction of antibody to pneumococcal polysaccharides.
    Clin Exp Immunol. 1986 Jan;63(1):127-34 PMID: 3955880
  48. Quantitative relationship between anticapsular antibody measured by enzyme-linked immunosorbent assay or radioimmunoassay and protection of mice against challenge with Streptococcus pneumoniae serotype 4.
    Infect Immun. 1990 Dec;58(12):3871-6 PMID: 2254015
  49. Towards a comprehensive view of immunoglobulin class switching.
    Immunol Today. 1993 Jan;14(1):15-7 PMID: 8442856
  50. Human C-reactive protein is protective against fatal Streptococcus pneumoniae infection in mice.
    J Immunol. 1982 May;128(5):2374-6 PMID: 7061864
  51. Identification of hydrogen peroxide as a Streptococcus pneumoniae toxin for rat alveolar epithelial cells.
    Infect Immun. 1993 Oct;61(10):4392-7 PMID: 8406830
  52. Mouse Igg3 antibodies are highly protective against infection with Streptococcus pneumoniae.
    Nature. 1981 Nov 5;294(5836):88-90 PMID: 6170000
  53. Immunogenicity of polysaccharides conjugated to peptides containing T- and B-cell epitopes.
    Infect Immun. 1994 Mar;62(3):785-92 PMID: 7509317
  54. Comparison of the induction of immunoglobulin M and G antibodies in mice with purified pneumococcal type 3 and meningococcal group C polysaccharides and their protein conjugates.
    Infect Immun. 1982 Jul;37(1):15-22 PMID: 6809623
  55. Purification and immunogenicity of genetically obtained pneumolysin toxoids and their conjugation to Streptococcus pneumoniae type 19F polysaccharide.
    Infect Immun. 1991 Jul;59(7):2297-304 PMID: 2050399
  56. Adherence of type I Streptococcus pneumoniae to tracheal epithelium of mice infected with influenza A/PR8 virus.
    Am Rev Respir Dis. 1986 Nov;134(5):1040-4 PMID: 3777666
  57. Naturally occurring antibodies to phosphocholine as a potential index of antibody responsiveness to polysaccharides.
    J Infect Dis. 1987 Jun;155(6):1307-14 PMID: 3572041
  58. Use of prior vaccinations for the development of new vaccines.
    Science. 1990 Jul 27;249(4967):423-5 PMID: 1696030
  59. Pneumococcal Forssman antigen: enrichment in mesosomal membranes and specific binding to the autolytic enzyme of Streptococcus pneumoniae.
    J Bacteriol. 1985 Jan;161(1):18-24 PMID: 2857159
  60. Plasma anti-pneumococcal antibody activity of the IgG class and subclasses in otitis prone children.
    Clin Exp Immunol. 1984 May;56(2):233-8 PMID: 6733969
  61. Correlation of serum opsonins with in vitro phagocytosis of Streptococcus pneumoniae.
    Infect Immun. 1985 Oct;50(1):213-7 PMID: 4044034
  62. Phosphorylcholine determinants in six pneumococcal capsular polysaccharides detected by monoclonal antibody.
    Infect Immun. 1984 Mar;43(3):876-8 PMID: 6199306
  63. Isotypes of antibodies induced by plain dextran or a dextran-protein conjugate.
    Eur J Immunol. 1985 Aug;15(8):827-33 PMID: 2411572
  64. Role of pneumococcal surface protein A in the virulence of Streptococcus pneumoniae.
    Rev Infect Dis. 1988 Jul-Aug;10 Suppl 2:S372-4 PMID: 3187321
  65. Inhibition of in vitro human lymphocyte response by the pneumococcal toxin pneumolysin.
    Infect Immun. 1984 Nov;46(2):585-9 PMID: 6389352
  66. Activation of the alternative complement pathway by pneumococcal cell wall teichoic acid.
    J Immunol. 1978 Jan;120(1):174-8 PMID: 24071
  67. Nonionic block polymer surfactants modulate the humoral immune response against Streptococcus pneumoniae-derived hexasaccharide-protein conjugates.
    Infect Immun. 1989 Sep;57(9):2712-8 PMID: 2759707
  68. Epidemiological studies of Streptococcus pneumoniae in infants: development of antibody to phosphocholine.
    J Clin Microbiol. 1983 Nov;18(5):1102-7 PMID: 6643664
  69. The cell wall mediates pneumococcal attachment to and cytopathology in human endothelial cells.
    Infect Immun. 1993 Apr;61(4):1538-43 PMID: 8454360
  70. Epidemiological studies of Streptococcus pneumoniae in infants: antibody to types 3, 6, 14, and 23 in the first two years of life.
    J Infect Dis. 1988 Nov;158(5):948-55 PMID: 3183428
  71. Rabbit antibodies to the cell wall polysaccharide of Streptococcus pneumoniae fail to protect mice from lethal challenge with encapsulated pneumococci.
    Infect Immun. 1986 Nov;54(2):448-55 PMID: 3095243
  72. Effects of chain length on the immunogenicity in rabbits of group B Streptococcus type III oligosaccharide-tetanus toxoid conjugates.
    J Clin Invest. 1992 Jan;89(1):203-9 PMID: 1729272
  73. Binding of C-reactive protein to the pneumococcal capsule or cell wall results in differential localization of C3 and stimulation of phagocytosis.
    J Immunol. 1984 Sep;133(3):1424-30 PMID: 6747291
  74. Infections caused by Streptococcus pneumoniae: clinical spectrum, pathogenesis, immunity, and treatment.
    Clin Infect Dis. 1992 Apr;14(4):801-7 PMID: 1576274
  75. Antibody to capsular polysaccharides of Streptococcus pneumoniae: prevalence, persistence, and response to revaccination.
    Clin Infect Dis. 1993 Jul;17(1):66-73 PMID: 8353248
  76. Antimicrobial resistance in Streptococcus pneumoniae: an overview.
    Clin Infect Dis. 1992 Jul;15(1):77-83 PMID: 1617076
  77. MHC interaction and T cell recognition of carbohydrates and glycopeptides.
    J Immunol. 1992 Apr 15;148(8):2446-51 PMID: 1560200
  78. Studies on the mechanism of the immunological paralysis induced in mice by pneumococcal polysaccharides.
    J Immunol. 1955 Jan;74(1):17-26 PMID: 13233513
  79. Structure of the complex polysaccharide C-substance from Streptococcus pneumoniae type 1.
    Biochemistry. 1980 Sep 30;19(20):4712-9 PMID: 7426624
  80. Immunogenicity and immunochemistry of Streptococcus pneumoniae capsular polysaccharides.
    Antonie Van Leeuwenhoek. 1990 Jun;58(1):1-47 PMID: 2195989
  81. Antibody recognition of the type 14 pneumococcal capsule. Evidence for a conformational epitope in a neutral polysaccharide.
    J Exp Med. 1989 Jun 1;169(6):2121-31 PMID: 2471773
  82. Surface components of Streptococcus pneumoniae.
    Rev Infect Dis. 1981 Mar-Apr;3(2):190-211 PMID: 7256084
  83. Preparation, characterization, and immunogenicity of Haemophilus influenzae type b polysaccharide-protein conjugates.
    J Exp Med. 1980 Aug 1;152(2):361-76 PMID: 6967514
  84. Attachment of oligosaccharides to peptide antigen profoundly affects binding to major histocompatibility complex class II molecules and peptide immunogenicity.
    Eur J Immunol. 1994 May;24(5):1066-72 PMID: 8181518
  85. Protective efficacy of pneumococcal polysaccharide vaccines.
    JAMA. 1977 Dec 12;238(24):2613-6 PMID: 21973
  86. Augmented anti-S 3 antibody responses to an S 3 -protein conjugate.
    J Immunol. 1971 Sep;107(3):685-8 PMID: 4105931
  87. Modulation of the immune response to pneumococcal type 14 capsular polysaccharide-protein conjugates by the adjuvant Quil A depends on the properties of the conjugates.
    Infect Immun. 1989 Apr;57(4):1078-83 PMID: 2925240
  88. Synthetic peptides representing T-cell epitopes act as carriers in pneumococcal polysaccharide conjugate vaccines.
    Infect Immun. 1995 Mar;63(3):961-8 PMID: 7532630
  89. STUDIES ON ANTIBACTERIAL IMMUNITY INDUCED BY ARTIFICIAL ANTIGENS : I. IMMUNITY TO EXPERIMENTAL PNEUMOCOCCAL INFECTION WITH AN ANTIGEN CONTAINING CELLOBIURONIC ACID.
    J Exp Med. 1939 Feb 28;69(3):353-64 PMID: 19870851
  90. Serotypic variations among virulent pneumococci in deposition and degradation of covalently bound C3b: implications for phagocytosis and antibody production.
    J Infect Dis. 1986 Apr;153(4):682-93 PMID: 3950449
  91. Monoclonal antibodies against protease-sensitive pneumococcal antigens can protect mice from fatal infection with Streptococcus pneumoniae.
    J Exp Med. 1984 Aug 1;160(2):386-97 PMID: 6381634
  92. Antibody response to pneumococcal vaccination in children younger than five years of age.
    J Infect Dis. 1983 Jul;148(1):131-7 PMID: 6886479
  93. Molecular analysis of the pathogenicity of Streptococcus pneumoniae: the role of pneumococcal proteins.
    Annu Rev Microbiol. 1993;47:89-115 PMID: 7903033
  94. A randomized comparison of three bivalent Streptococcus pneumoniae glycoprotein conjugate vaccines in young children: effect of polysaccharide size and linkage characteristics.
    Pediatr Infect Dis J. 1994 May;13(5):368-72 PMID: 8072818
  95. Thymus-independent and thymus-dependent responses to polysaccharide antigens.
    J Infect Dis. 1992 Jun;165 Suppl 1:S49-52 PMID: 1588177
  96. Defective antipneumococcal polysaccharide antibody response in children with recurrent respiratory tract infections.
    J Allergy Clin Immunol. 1993 Jan;91(1 Pt 1):110-9 PMID: 8423268
  97. Production of opsonins that facilitate phagocytosis of Streptococcus pneumoniae by human alveolar macrophages or neutrophils after vaccination with pneumococcal polysaccharide.
    Am Rev Respir Dis. 1981 Aug;124(2):193-5 PMID: 7258831
  98. Studies on functional subpopulations of B cells in mice. Correction of the immune defect of CBA/N mice by transfer of C3 receptor-bearing B cells.
    Cell Immunol. 1981 Jul 1;61(2):386-96 PMID: 6972813
  99. Pneumococcal polysaccharide vaccine in young adults and older bronchitics: determination of IgG responses by ELISA and the effect of adsorption of serum with non-type-specific cell wall polysaccharide.
    J Infect Dis. 1990 Apr;161(4):728-35 PMID: 2319166
  100. Covalent linkage between the capsular polysaccharide and the cell wall peptidoglycan of Streptococcus pneumoniae revealed by immunochemical methods.
    Microb Pathog. 1990 May;8(5):325-34 PMID: 2215183
  101. Mechanisms of host defense against infection with Streptococcus pneumoniae.
    Clin Infect Dis. 1992 Jan;14(1):251-62 PMID: 1571441
  102. Regulation of the anti-alpha(1----3) dextran IgG antibody response of BALB/c mice by idiotype-specific T suppressor lymphocytes.
    J Immunol. 1990 Jan 1;144(1):53-9 PMID: 1688575
  103. Bacterial capsular polysaccharides--biochemistry, immunity and vaccine.
    Mol Immunol. 1987 Oct;24(10):1005-19 PMID: 3119993
  104. Cell biology of B lymphocyte activation by polysaccharides.
    J Infect Dis. 1992 Jun;165 Suppl 1:S71-3 PMID: 1588183
  105. Glycopeptides bind MHC molecules and elicit specific T cell responses.
    J Immunol. 1993 Sep 1;151(5):2419-25 PMID: 8360471
  106. Glycoconjugates of bacterial carbohydrate antigens. A survey and consideration of design and preparation factors.
    Contrib Microbiol Immunol. 1989;10:48-114 PMID: 2684507
  107. Human antibody responses to two conjugate vaccines of Haemophilus influenzae type B saccharides and diphtheria toxin.
    Scand J Immunol. 1988 Oct;28(4):471-9 PMID: 3264084
  108. Interruption of capsule production in Streptococcus pneumonia serotype 3 by insertion of transposon Tn916.
    Infect Immun. 1990 Sep;58(9):3135-8 PMID: 2167295
  109. Identification of an active disaccharide unit of a glycoconjugate receptor for pneumococci attaching to human pharyngeal epithelial cells.
    J Exp Med. 1983 Aug 1;158(2):559-70 PMID: 6886624
  110. Secretory immunity and the bacterial IgA proteases.
    Rev Infect Dis. 1981 May-Jun;3(3):521-34 PMID: 6792682
  111. Thymus-independence of slowly metabolized immunogens.
    Proc Natl Acad Sci U S A. 1972 Sep;69(9):2696-700 PMID: 4115955
  112. The effect of Streptococcus pneumoniae pneumolysin on human respiratory epithelium in vitro.
    Microb Pathog. 1990 Oct;9(4):275-84 PMID: 2097494
  113. Ultrastructural localization of capsules, cell wall polysaccharide, cell wall proteins, and F antigen in pneumococci.
    Infect Immun. 1988 Aug;56(8):1890-6 PMID: 3397179
  114. Studies on artificial oligosaccharide-protein antigens: induction of precipitating antibodies to defined epitopes on natural and synthetic dextrans and mannans.
    Mol Immunol. 1985 Jan;22(1):29-36 PMID: 2579326
  115. Production of interleukin-1 but not tumor necrosis factor by human monocytes stimulated with pneumococcal cell surface components.
    Infect Immun. 1989 Jul;57(7):1890-3 PMID: 2786503
  116. Effect of oligosaccharide chain length, exposed terminal group, and hapten loading on the antibody response of human adults and infants to vaccines consisting of Haemophilus influenzae type b capsular antigen unterminally coupled to the diphtheria protein CRM197.
    J Immunol. 1989 Apr 1;142(7):2464-8 PMID: 2784464
  117. Measurement of antibody responses to pneumolysin--a promising method for the presumptive aetiological diagnosis of pneumococcal pneumonia.
    J Infect. 1989 Sep;19(2):127-34 PMID: 2809235
  118. Protein-conjugated synthetic di- and trisaccharides of pneumococcal type 17F exhibit a different immunogenicity and antigenicity than tetrasaccharide.
    Vaccine. 1993 Nov;11(14):1429-36 PMID: 8310762
  119. Aspects of pneumococcal infection including bacterial virulence, host response and vaccination.
    J Med Microbiol. 1989 Apr;28(4):237-48 PMID: 2649678
  120. C-reactive protein is protective against Streptococcus pneumoniae infection in mice.
    J Exp Med. 1981 Nov 1;154(5):1703-8 PMID: 7299351
  121. Inhibition of human polymorphonuclear leukocyte respiratory burst, bactericidal activity, and migration by pneumolysin.
    Infect Immun. 1983 Sep;41(3):1212-6 PMID: 6885160
  122. T helper cell-dependent B cell activation.
    FASEB J. 1991 Oct;5(13):2770-6 PMID: 1833257
  123. Induction of pulmonary inflammation by components of the pneumococcal cell surface.
    Am Rev Respir Dis. 1987 Apr;135(4):869-74 PMID: 3565933
  124. Oligosaccharide-protein conjugate vaccines induce and prime for oligoclonal IgG antibody responses to the Haemophilus influenzae b capsular polysaccharide in human infants.
    J Exp Med. 1986 Feb 1;163(2):262-9 PMID: 3484778
  125. Subclass restriction of murine anti-carbohydrate antibodies.
    J Immunol. 1978 Aug;121(2):566-72 PMID: 79606
  126. Development of IgG antipolyribosylribitolphosphate antibodies in the course of H. influenzae type b meningitis in infants below 2 years of age.
    Monogr Allergy. 1988;23:282-8 PMID: 3260338
  127. Antibodies against pneumococcal C-polysaccharide are not protective.
    Microb Pathog. 1993 Apr;14(4):299-305 PMID: 8326853
  128. Antipneumococcal effects of C-reactive protein and monoclonal antibodies to pneumococcal cell wall and capsular antigens.
    Infect Immun. 1989 May;57(5):1457-64 PMID: 2707854
  129. THE PROTECTIVE ACTION OF A SPECIFIC ENZYME AGAINST TYPE III PNEUMOCOCCUS INFECTION IN MICE.
    J Exp Med. 1931 Jun 30;54(1):73-89 PMID: 19869903
  130. Non-epitope-specific suppression of the antibody response to Haemophilus influenzae type b conjugate vaccines by preimmunization with vaccine components.
    Infect Immun. 1993 Feb;61(2):432-8 PMID: 7678586
  131. Antigenicity of dextran-protein conjugates in mice. Effect of molecular weight of the carbohydrate and comparison of two modes of coupling.
    J Immunol. 1989 Aug 15;143(4):1259-64 PMID: 2473126
  132. Toxicity of pneumolysin to pulmonary alveolar epithelial cells.
    Infect Immun. 1993 Apr;61(4):1352-8 PMID: 8454338
  133. The human in vitro anti-type 4 pneumococcal polysaccharide antibody response is regulated by suppressor T cells.
    Scand J Immunol. 1991 Aug;34(2):229-36 PMID: 1830972
  134. PspA, a surface protein of Streptococcus pneumoniae, is capable of eliciting protection against pneumococci of more than one capsular type.
    Infect Immun. 1991 Jan;59(1):222-8 PMID: 1987036
  135. Use of insertional inactivation to facilitate studies of biological properties of pneumococcal surface protein A (PspA).
    J Exp Med. 1987 Feb 1;165(2):381-94 PMID: 3546575
  136. Analysis of pneumococcal PspA microheterogeneity in SDS polyacrylamide gels and the association of PspA with the cell membrane.
    Microb Pathog. 1992 Nov;13(5):343-55 PMID: 1297913
  137. Evaluation of the role of the pneumococcal Forssman antigen (F-polysaccharide) in the cross-serotype protection induced by pneumococcal subcellular preparations.
    Infect Immun. 1981 Jan;31(1):169-73 PMID: 7216443
  138. Optimal conditions for the opsonophagocytosis test with Streptococcus pneumoniae serotypes 3, 6A, 7F and 19F and human granulocytes.
    Acta Pathol Microbiol Immunol Scand C. 1986 Jun;94(3):105-11 PMID: 3751584
  139. CHEMO-IMMUNOLOGICAL STUDIES ON CONJUGATED CARBOHYDRATE-PROTEINS : I. THE SYNTHESIS OFp-AMINOPHENOL beta-GLUCOSIDE, p-AMINOPHENOL beta-GALACTOSIDE, AND THEIR COUPLING WITH SERUM GLOBULIN.
    J Exp Med. 1929 Sep 30;50(4):521-31 PMID: 19869644
  140. Role of CR2 in the human adult and neonatal in vitro antibody response to type 4 pneumococcal polysaccharide.
    Cell Immunol. 1992 Aug;143(1):11-22 PMID: 1535831
  141. In vivo isotype regulation of humoral responses to dextran B1355 in BALB/c mice. Double-class IgG3/IgM producers as a function of age.
    Scand J Immunol. 1985 Feb;21(2):173-81 PMID: 2579418
  142. Effect of genetic switching of capsular type on virulence of Streptococcus pneumoniae.
    Infect Immun. 1994 May;62(5):1813-9 PMID: 8168944
  143. Vaccination and revaccination with polyvalent pneumococcal polysaccharide vaccines in adults and infants.
    Proc Soc Exp Biol Med. 1978 Jan;157(1):148-54 PMID: 23549
  144. Induction of phosphocholine-specific antibodies in X-linked immune deficient mice: in vivo protection against a Streptococcus pneumoniae challenge.
    Int Immunol. 1994 Apr;6(4):561-8 PMID: 8018596
  145. Many pulmonary pathogenic bacteria bind specifically to the carbohydrate sequence GalNAc beta 1-4Gal found in some glycolipids.
    Proc Natl Acad Sci U S A. 1988 Aug;85(16):6157-61 PMID: 3413084
  146. Epidemiologic studies of Streptococcus pneumoniae in infants: antibody response to nasopharyngeal carriage of types 3, 19, and 23.
    J Infect Dis. 1981 Oct;144(4):312-8 PMID: 7288212
  147. Comparative efficacy of pneumococcal neuraminidase and pneumolysin as immunogens protective against Streptococcus pneumoniae.
    Microb Pathog. 1988 Dec;5(6):461-7 PMID: 3149709
  148. Effect of carrier priming on immunogenicity of saccharide-protein conjugate vaccines.
    Infect Immun. 1991 Oct;59(10):3504-10 PMID: 1894357
  149. Comparative efficacy of autolysin and pneumolysin as immunogens protecting mice against infection by Streptococcus pneumoniae.
    Microb Pathog. 1992 Feb;12(2):137-43 PMID: 1350045
  150. Evaluation of the opsonic requirements for phagocytosis of Streptococcus pneumoniae serotypes VII, XIV, and XIX by chemiluminescence assay.
    Infect Immun. 1981 Jan;31(1):228-35 PMID: 7216447
  151. A brief history of the pneumococcus in biomedical research: a panoply of scientific discovery.
    Clin Infect Dis. 1993 Nov;17(5):913-24 PMID: 8286641
  152. Epidemiology of pediatric meningitis caused by Haemophilus influenzae type b, Streptococcus pneumoniae, and Neisseria meningitidis in Israel: a 3-year nationwide prospective study. Israeli Pediatric Bacteremia and Meningitis Group.
    J Infect Dis. 1994 Apr;169(4):912-6 PMID: 8133109
  153. Pathogenesis of pneumococcal pneumonia.
    Rev Infect Dis. 1991 May-Jun;13 Suppl 6:S509-17 PMID: 1862280
  154. Effect of immunization with pneumolysin on survival time of mice challenged with Streptococcus pneumoniae.
    Infect Immun. 1983 May;40(2):548-52 PMID: 6840851
  155. A 43-kilodalton pneumococcal surface protein, PspA: isolation, protective abilities, and structural analysis of the amino-terminal sequence.
    Infect Immun. 1991 Apr;59(4):1285-9 PMID: 2004810
  156. The percentages of six immunoglobulin isotypes in human antibodies to tetanus toxoid: standardization of isotype-specific second antibodies in solid-phase assay.
    Eur J Immunol. 1984 Sep;14(9):868-75 PMID: 6479211
  157. Pneumococcal type-associated variability in alternate complement pathway activation.
    Infect Immun. 1975 Oct;12(4):772-8 PMID: 329
  158. Triggering of pneumococcal autolysis by lysozyme.
    J Infect Dis. 1993 Mar;167(3):684-90 PMID: 8095061
Article Info
Journal
Microbiological reviews
Abbr.
Microbiol Rev
ISSN
0146-0749
DOI
10.1128/mr.59.4.591-603.1995
Published
1995-12-00
Pages
591-603
Language
English
Region
United States
NLM ID
7806086
PMCID
PMC239389
Subset
IM
External Links
PubMed source DOI: 10.1128/mr.59.4.591-603.1995 PMC Full Text
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2